BioTuesdays

Author - Melane Sampson

Knight Therapeutics

Knight files NDS for CREXONT in Canada

Knight Therapeutics (TSX: GUD) has announced that its new drug submission (NDS) for CREXONT—a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease—has...

Bryan Baum joins Senti’s BOD

Senti Bio (NASDAQ: SNTI) has announced the appointment of entrepreneurial leader and investor Bryan Baum to its board of directors (BOD). Mr. Baum is the co-founder and managing partner of K5 Global. His portfolio...